Thermo Fisher Scientific Cambridge Facility Wins the Queens Award for Enterprise in 2009
News Apr 29, 2009
Thermo Fisher Scientific Inc. has announced that its Cambridge facility has been awarded a Queens Award for Enterprise 2009 in the Outstanding Innovation category for the iCAP 6000 Series ICP-OES instrument. This award recognizes the iCAP 6000 as one of the year’s most outstanding technical innovations.
The Thermo Scientific iCAP 6000 Series ICP-OES (Inductively Coupled Plasma, Optical Emission Spectrometry) instruments are used in laboratories to detect and measure low levels of toxic or pollutant elements in a wide range of samples.
The Queens Award for Enterprise recognizes the novel design of the iCAP 6000 which delivers outstanding performance, ease of use and low cost of ownership, all in a compact instrument. Specifically developed for environmental, metallurgical, petrochemical and food safety applications, this compact instrument provides users in laboratories with increased analysis speed, stability and trace (parts per billion) level detection capabilities.
The Thermo Fisher Scientific team in Cambridge started work on the design of the iCAP 6000 in 2002 and has been manufacturing the product and distributing it world wide since 2006. Since its launch, the iCAP 6000 has captured a significant share of global markets in a number of important applications segments.
“The whole Cambridge team is delighted to be associated with a product which has been selected for this award” comments Paul Gillyon, product group director, Trace Elemental Analysis, Thermo Fisher Scientific.
“We work very hard to solve the technical challenges in developing complex instruments like the iCAP 6000 and to achieve commercial success with scientists in laboratories around the world. The Queens Award recognizes all the expertise, hard work and commitment that has been contributed by all the members of the Cambridge team.”
The Queen’s representative in Cambridge will make a formal presentation of the award at the Thermo Fisher Scientific facility, later in 2009.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE